 Aeglea Bio Therapeutics NASDAQ:AGLE was downgraded by equities researchers at BidaskClub from a hold rating to a sell rating in a research note issued to investors on Thursday, BidAskClub reports. Other equities analysts also recently issued research reports about the stock. HC Wainwright dropped their price target on shares of Aeglea Bio Therapeutics from 18.00 ... 